ADA Scientific Sessions 2026 Abstract · Jun 5, 2026

Long-Term Effects of Metformin and Lifestyle Interventions on Ankle-Brachial Index in the Diabetes Prevention Program Outcomes Study (DPPOS)

By GARIMELLA PS, MELE LM, BOYKO E et al.

Introduction and Objective: Peripheral artery disease is marked by abnormal ankle-brachial index (ABI): low ABI (<0.90) reflects atherosclerotic disease, while high ABI (≥1.30) suggests medial arterial calcification, each with distinct cardiovascular risks. This study evaluated effects of lifestyle and metformin interventions on ABI progression and identified clinical correlates of abnormal ABI development over 14 years in adults with prediabetes. Methods: Among 3,234 Diabetes Prevention Program (DPP) participants randomized to lifestyle intervention, metformin, or placebo, serial ABI measurements were obtained pre-randomization (baseline) and 1, 3, 8, and 14 years after randomization. Multivariable logistic regression identified factors associated with progression from normal at baseline to low or high ABI at year 14. Results: At baseline, mean age was 51 years, 69% were female, and 20% identified as Black or African American. Low ABI prevalence was modest (peak prevalence of 7.5% by year 14), while high ABI prevalence reached 33% by year 14. Randomization to lifestyle intervention was associated with 57% lower odds of progression to low ABI (adjusted OR=0.43, 95% CI 0.24-0.77, p=0.005) relative to placebo; metformin showed no benefit. Randomization to metformin was associated with higher odds of progression to high ABI (adjusted OR=1.35, 95% CI 1.04-1.77, p=0.027) relative to placebo; lifestyle was not significantly associated with high ABI. Older age and higher fasting glucose at baseline were associated with progression to low ABI, while female sex and higher baseline level of hsCRP (mean=0.59 mg/dL) were protective against high ABI. These divergent risk-factor profiles indicate potential distinct pathophysiological mechanisms. Conclusion: Among persons with prediabetes lifestyle modification may reduce the risk of atherosclerotic low ABI while metformin may raise risk of high ABI. Distinct metabolic and inflammatory profiles may underlie progression to low versus high ABI. Disclosure: P.S. Garimella: Consultant; Current; Otsuka America Pharmaceutical, Inc. L.M. Mele: None. E. Boyko: None. T. Orchard: None. N. Mathioudakis: None. U. Ibebuogu: None. W. Knowler: None. D. Dabelea: None. M. Temprosa: None. D. Research Group: None. Funding: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) U01 DK048489, National Institute on Aging of the NIH 5 U19 AG078558.

doi.org/10.2337/db26-1418-pInterventions

AgingResearch.News